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F irst-degree relatives of patients with nonsyndromic colorectal cancer (CRC) are at higher risk of developing CRC than the general population. 1, 2 Personal risk in these individuals has mostly been related to the age of the index case at diagnosis, degree of kinship, and number of relatives affected. Having a first-degree relative with CRC diagnosed after the age of 60 years is associated with an almost 2-fold increase in personal risk, 3 and this increases to 4-fold when CRC in the index case is diagnosed before the age of 55 years. 1, 4 In addition, the risk of developing advanced adenoma or CRC is about 3-fold higher if a sibling is affected 5, 6 and even higher when there are 2 or more first-degree relatives with CRC, 1,2 regardless of age at diagnosis. Based on this evidence, current practice guidelines recommend that subjects with CRC familial aggregation should be subject to more intensive screening strategies than the average-risk population. Although there is no uniform approach among scientific societies, most recommend colonoscopy every 5 years, starting at the age of 40, or 10 years younger than the index case at diagnosis. [7] [8] [9] [10] These recommendations are based on empirical evidence, as no study has clearly demonstrated the efficacy of this policy to reduce CRC mortality or incidence in this population. However, the efficacy of colonoscopy screening in asymptomatic first-degree relatives of patients with CRC is clearly hampered by suboptimal compliance. 11 Two major factors contribute to this low screening uptake. First, screening in these individuals is mostly opportunistic, as they are currently excluded from population-based programs in most countries; and second, there is ample evidence showing underutilization of colonoscopy at the recommended intervals in this population. [12] [13] [14] [15] [16] [17] Tentative solutions to improve screening uptake in familial CRC include incorporating these individuals in average-risk population-based programs, as recently recommended by the European Guidelines, 18 and/or offering them alternative screening strategies with inferior detection yield but better acceptance than colonoscopy. In this regard, observational studies have shown that fecal immunochemical testing (FIT) has acceptable performance for detecting colorectal neoplasia in asymptomatic first-degree relatives of patients with CRC. Although randomized controlled trials on the efficacy of FIT vs colonoscopy in familial CRC are lacking, observational studies suggest that FIT has acceptable performance for detecting advanced neoplasia (advanced adenoma or CRC) in asymptomatic first-degree relatives of patients with CRC. 19, 20 In addition, a recent study suggested that using FIT in the intervals of surveillance colonoscopies is useful to detect missed or rapidly developing colorectal neoplasms in this moderate-risk population. 21 All together, these data support the notion that FIT screening could be an alternative strategy to colonoscopy in the familial-risk population, with better screening uptake and acceptable performance.
We hypothesized that repeated FIT screening is equivalent to one-time colonoscopy for detecting advanced colorectal neoplasms in familial CRC. We therefore conducted a controlled randomized trial to compare the efficacy of annual FIT vs one-time colonoscopy for detecting advanced neoplasia in asymptomatic first-degree relatives of patients with CRC.
Methods

Study Population
Between January 2006 and December 2010, consecutive first-degree relatives (parents, siblings, or offspring) of patients with nonsyndromic CRC referred for screening to the high-risk CRC clinic of the University Hospital of the Canary Islands, were assessed for enrollment. This outpatient clinic coordinates the diagnosis and surveillance of patients with hereditary CRC syndromes, screening of first-degree relatives of nonsyndromic index cases and surveillance of patients with advanced colorectal neoplasia in a health area serving approximately 375,000 inhabitants. Therefore, first-degree relatives referred for screening came either from family doctors or gastroenterologists attending the reference health area or from the admissions department of the reference hospital, which provided an appointment for CRC index cases after surgical or oncologic treatment.
First-degree relatives and index cases were personally interviewed by a gastroenterologist (MC, AZG, MH, or IA) and completed a questionnaire about demographic data, their own medical history, and their family history of cancer (ie, number of affected relatives, age, sex, place of residence, and Amsterdam II criteria). 22 The enrollment criteria were asymptomatic first-degree relatives aged 40 years or older or 10 years younger than the youngest case in the family, confirmed CRC diagnosis of the index cases and their respective relatives by written (endoscopic, histopathologic, or clinical) report or documented by their family doctors, and having signed the informed consent form. Exclusion criteria were having previously undergone CRC screening, belonging to a high-risk group due to hereditary CRC syndrome, having a personal history of inflammatory bowel disease or colorectal neoplasia (any adenoma or CRC), having symptoms suggestive of colorectal disease (ie, rectal bleeding, altered frequency of bowel movements, constitutional symptoms, and anemia), and suffering from a serious illness (disease with a mean life expectancy of <5 years or chronic disease with performance status !2).
Eligible first-degree relatives and index cases were given a leaflet with detailed information about the study and were asked to invite any first-degree relatives older than 18 years to participate in the study. We encouraged them to pass on to their first-degree relatives the leaflet about the study and to stimulate their participation. For this purpose, a contact telephone number was given to arrange appointments with the study coordinator.
All authors had access to the study data and reviewed and approved the final manuscript. The Clinical Research Ethics Committee of our center approved the study protocol, on condition that colonoscopy was offered to all subjects with a negative FIT result over 36 months. The trial, registered as ClinicalTrials.gov number NCT01075633, was checked for compliance with the CONSORT (Consolidated Standards of Reporting Trials) checklist.
Randomization and Masking
To ensure that all first-degree relatives of each index case received the same screening strategy, families were randomly assigned to receive annual FIT and colonoscopy in case of a positive result or one-time colonoscopy in a 1:1 ratio, using a computer-generated list, concealed in sequentially numbered, sealed, opaque envelopes. Randomization was performed before signed informed consent was obtained. Eligible firstdegree relatives received detailed written and verbal information about the screening strategy to which they were assigned. The study design allowed for crossover between the 2 screening strategies in the event of participant disagreement with their initial group assignment.
Fecal Immunochemical Testing
Individuals assigned to the FIT group were provided with a single OC-Sensor (Eiken Chemical Co., Tokyo, Japan) kit per year during 3 consecutive years with automated analysis of results, as described previously. 23 No specific indications on diet or medication were given. Participants were asked to keep fecal samples at 4 C and return them within 5 days after sampling. The cutoff to indicate colonoscopy was established at !10 mg hemoglobin (Hb)/g of feces (equivalent to !50 ng Hb/mL buffer). 24 We chose a low cutoff threshold because our population was not average risk and we wished to detect all CRC present on the first screen if possible. Patients with a positive result were scheduled for colonoscopy within 6 weeks. The quality of FIT measurements was assured by daily calibration and external validation with samples provided by the manufacturer every 6 months. Subjects assigned to the FIT group were considered compliant if they completed at least one FIT.
Colonoscopy
Colonoscopies were performed by 4 experienced endoscopists (regularly performing >200 such procedures per year) who were blinded to group assignment. Colonic cleansing and sedation was performed as described previously. 25 Colonoscopy was considered complete if the cecum was reached and the bowel-cleansing score in each segment was good or excellent, as described previously. 25 Cecal intubation was photographically documented. Cases not meeting these requirements were rescheduled for colonoscopy. Findings were documented in a standardized report form. Detected lesions were grouped as proximal or distal to the splenic flexure. Adenomas !10 mm in size, with tubulovillous or villous architecture, high-grade dysplasia, or intramucosal carcinoma (pTis) were classified as advanced adenomas. Invasive cancer was considered to be present when malignant cells were observed beyond the muscularis mucosa. Advanced neoplasia was defined as advanced adenoma or invasive cancer. The size of the polyps was established ex vivo after resection and before formaldehyde fixation. Tumor staging was performed according to the classification system of the American Joint Committee on Cancer, 26 and patients were classified according to the most advanced lesion.
In both groups, patients with advanced adenomas were scheduled for surveillance colonoscopy 3 years after polypectomy. 8 In the colonoscopy group, a follow-up colonoscopy was scheduled 5 years after the baseline colonoscopy in all subjects who had no advanced neoplasia in the former procedure.
Follow-up
Participants were actively followed until August 31, 2013. To determine false-negative results, all subjects with a negative FIT result were invited to undergo colonoscopy at study completion. In the FIT group, a follow-up colonoscopy was defined as that performed after at least 2 negative FIT results, and an interval colonoscopy was defined as any colonoscopy performed after a negative first FIT result. In the colonoscopy group, interval colonoscopy referred to colonoscopies performed within 36 months after a baseline colonoscopy.
Deaths, interval CRCs, and interval colonoscopies were identified through cross-linkage of the study database and the regional intranet network that provided access to the electronic medical record and with the Canary Islands cancer registry. Interval cancer was defined as cancer occurring between 6 and 36 months after a negative screening colonoscopy. 27 
Statistical Analysis and Sample Size
The primary objective was to determine whether annual FIT was equivalent to one-time colonoscopy for detecting advanced neoplasia in first-degree relatives of patients with CRC. We considered equivalence to be demonstrated when the 95% confidence intervals (CI) of the absolute difference in the probability of detecting advanced neoplasia between both strategies did not exceed the equivalence boundary of ±3%, according to per-protocol and intention-to-screen analyses. 28, 29 We assumed a probability of participation, detection capability, and prevalence of advanced neoplasia for FIT of 0.750, 0.565, and 0.077, respectively, the product of which was 0.033. In the case of colonoscopy, the likelihood of participation, detection capability, and prevalence of advanced neoplasia was 0.500, 0.965, and 0.077, respectively, and their product was 0.037. Accordingly, for a type I error (a) of 0.05 and a power of 0.80, the number of first-degree relatives to be included was 1488 (744 per group) (STAT-XACT 5 statistical software). 30 In addition, we compared the efficacy of FIT vs colonoscopy to detect advanced neoplasia on the basis of different estimated participation rates, assuming a 5%-20% higher uptake for the FIT group than for the colonoscopy group.
The equivalence analysis was performed taking into account both per-protocol and intention-to-screen analyses. 27, 28 The per-protocol population was defined as first-degree relatives that satisfied the inclusion and none of the exclusion criteria, and actually received the strategy to which they were assigned. In the intention-to-screen analysis, first-degree relatives were analyzed according to their randomly assigned strategy, irrespective of whether they actually received it or not. In the FIT group, subjects complying with at least 1 of 3 screening rounds were considered for per-protocol and intention-to-screen analysis.
The efficacy of FIT to detect advanced neoplasia after 1, 2, or 3 positive tests was performed on the basis of as-screened analysis, defined as the number of subjects with true positive results divided by the number of subjects who finally underwent FIT or colonoscopy testing, irrespective of initial randomized assignment.
Comparison of advanced neoplasia detection rate between subjects undergoing FIT or colonoscopy screening according to demographic data and family history was performed on the basis of as-screened analysis. Statistical comparisons for secondary end points (overall quality of colonoscopy preparation, cecum intubation rate, compliance, and adverse events) were calculated by logistic-regression analysis and reported as odds ratios (OR) with 95% CI. A P value <.05 was considered to indicate statistical significance using a 2-sided test of proportions. These analyses were performed using SPSS software, version 15 (IBM SPSS, Armonk, NY).
Results
Overall, 6472 first-degree relatives of 972 index cases were randomly assigned to either direct colonoscopy or FIT screening during 3 consecutive years. Of these, 4554 (70.4%) were not contacted or declined the invitation to participate in the study. Among the 1918 (29.6%) who were contacted, 352 were excluded (170 in the colonoscopy group and 182 in the FIT group), as they did not meet the inclusion criteria ( Figure 1 ). Of all eligible first-degree relatives, the final study sample consisted of 782 first-degree relatives from 543 index cases in the colonoscopy group and 784 first-degree relatives from 429 index cases in the FIT group.
No significant differences between the 2 groups were found with regard to age group, sex, kinship, age of the index case, rate of complete colonoscopies and compliance with the assigned strategy ( Table 1) . Crossover was significantly higher among participants assigned to the FIT group (6.5%) as compared with the colonoscopy group (1.9%) (P < .001) ( Table 1) .
According to screening actually performed, 798 (97.5%) of 818 first-degree relatives belonging to the colonoscopy group finally underwent colonoscopy and in the FIT group, 724 (96.8%) of 748 first-degree relatives underwent at least 1 FIT (Figure 1 ). Among first-degree relatives receiving FIT, 272 (37.5%) completed 3 tests, 254 (35.1%) completed 2 tests and 198 (27.3%) completed 1 test. The majority (72.6 %) of participants completed at least 2 FIT. Of these, 112 (15.5%) tested positive and all of these underwent colonoscopy. Table 2 shows the diagnostic yield in patients with a positive FIT after the performance of the first, the second, or the third test. Twenty-three of 29 (79.1%) advanced neoplasias were detected after the first FIT. Advanced neoplasia was found in 48 (6.0%) first-degree relatives undergoing screening colonoscopy and in 29 Figure 1 . Inclusion, exclusion, and screening test outcomes in first-degree relatives of patients with colorectal cancer. Overall, 2616 first-degree relatives refused the invitation to participate and 1938 were not contacted after being randomly assigned to either interval FIT or colonoscopy because they were not residents of the reference health area served by our hospital, did not attend the appointment made by the high-risk CRC clinic or had died. Criteria for exclusion were a personal history of inflammatory bowel disease, colorectal polyps or CRC, a family history of hereditary CRC, having previously undergone CRC screening with fecal occult blood testing, colonoscopy or sigmoidoscopy, having abdominal symptoms or refusal to participate.
(4.0%) of those screened by FIT (OR ¼ 1.53; 95% CI: 0.95-2.46; P ¼ .08). In addition, there was no significant difference in overall advanced neoplasia detection rate between groups when stratified according to first-degree relative age or sex, index-case age, kinship, or the number of relatives with CRC (Table 3) . Tumor staging showed 3 CRC stage I and 1 stage II in the FIT group and 4 CRC stage I and 2 stage III in the colonoscopy group. a Colonoscopy that reached the cecum and had adequate bowel preparation (at least 90% of the mucosal surface was explored).
b Advanced adenoma was defined as an adenoma measuring !10 mm in diameter, with villous architecture, high-grade dysplasia, or intramucosal carcinoma. c Advanced neoplasia was defined as advanced adenoma or cancer. Refers to subjects who agreed to participate in the study but did not comply with any strategy. c Refers to the cumulative positive FIT result. The denominator corresponds to the number of subjects that returned FIT for analysis (n ¼ 709 in the FIT group and 15 crossovers in the colonoscopy group). Colonoscopy that reached the cecum and had adequate (good or excellent) bowel preparation. e For the FIT group, the denominator corresponds to the number of subjects with a positive test. f The denominator corresponds to the sum of subjects who underwent colonoscopy after a positive result in the FIT group (n ¼ 111) plus the number of subjects that underwent colonoscopy (n ¼ 747) in the colonoscopy group.
Main Study Outcomes
In the intention-to-screen analysis (Table 4) , advanced neoplasia was detected in 44 (5.6%) subjects in the colonoscopy group vs 33 subjects (4.2%) in the FIT group (OR ¼ 1.41; 95% CI: 0.88-2.26; P ¼ .14). Nonadvanced adenomas were found in 148 (18.9%) subjects in the colonoscopy group vs 52 (6.6%) in the FIT group (OR ¼ 3.49; 95% CI: 2.49-4.91); P < .001). In the per-protocol analysis (Table 4) , advanced neoplasia was detected in 43 (5.8%) subjects in the colonoscopy group vs 28 (3.9%) in the FIT group (OR ¼ 1.56; 95% CI: 0.95-2.56; P ¼ .08). Nonadvanced adenomas were detected in 148 (19.8%) subjects in the colonoscopy group vs 38 (5.4%) in the FIT group (OR ¼ 4.71; 95% CI: 3.22-6.89; P < .001).
Supplementary Table 1 shows the results of the equivalence analysis, for which we estimated a 5%-20% higher participation rate in the FIT group than in the colonoscopy group. Overall, the 95% CI for the difference in probability of detecting advanced neoplasia between both strategies was within the pre-established ±3% error margin, both in the intention-to-screen analysis and in the per-protocol analysis.
The number of first-degree relatives who needed to be screened to detect one advanced neoplasia was 25 in the FIT group and 16 in the colonoscopy group. However, the numbers of subjects who needed to undergo colonoscopy to find any advanced neoplasia were 4 and 18, respectively. Table 5 summarizes the follow-up data. A follow-up colonoscopy was performed in 475 of 485 first-degree relatives (97.9%) with at least 2 negative FIT results, resulting in the detection of 12 advanced adenomas. In addition, an interval colonoscopy was performed in 53 of 127 firstdegree relatives (41.7%) with a single negative FIT result, resulting in the detection of 4 advanced adenomas. In total, 528 colonoscopies were performed in 612 first-degree relatives (86.3%) with a negative FIT result, resulting in the detection of 16 advanced adenomas. Therefore, 16 (39%) of 41 advanced adenomas were not detected by FIT. In 8 of these patients (19.5% of the 41), advanced adenomas were detected after 3 negative FIT results and in 4 cases (9.8%) after 1 and 2 negative FIT results, respectively. Eleven of 16 advanced adenomas not detected by FIT were located proximal to the splenic flexure.
Follow-up
In the colonoscopy group, 128 of 324 first-degree relatives (39.5%) without advanced neoplasia at baseline colonoscopy who had completed 60 months of follow-up underwent colonoscopy with 2 advanced adenomas detected. In addition, 15 first-degree relatives underwent an interval colonoscopy, with no lesions detected. CRC was not found in either group.
Post-polypectomy surveillance was performed in 20 of 25 (80%) first-degree relatives with advanced adenoma in the NOTE. In the as-screened analysis, the detection rate was calculated as the number of subjects with true positive results divided by the number of subjects who finally underwent testing. Subjects were classified according to the most advanced lesion. a Advanced neoplasia was defined as advanced adenoma or cancer.
b
Odds ratios were adjusted according to age, sex, age (younger than 60 years or 60 years or older) of the index case at diagnosis of CRC, presence of siblings or !2 first-degree relatives with CRC. NOTE. In the as-screened analysis, calculations were based on the number of subjects with true-positive results divided by the number of subjects who finally underwent testing. a Colonoscopies performed after at least 2 negative FIT results in first-degree relatives assigned to the FIT group or after 36 months in first-degree relatives with a baseline colonoscopy without advanced neoplasia in the colonoscopy group that had completed 60 months of follow-up.
b Advanced adenoma was defined as an adenoma measuring !10 mm in diameter, with villous architecture, high-grade dysplasia, or intramucosal carcinoma. c Interval colonoscopy in the FIT group was defined as any colonoscopy performed after a negative first FIT, and in the colonoscopy group it refers to colonoscopies performed within 36 months after baseline colonoscopy. Refers to colonoscopies performed 36 months after polypectomy, in subjects with advanced adenoma at the baseline colonoscopy in either group. e Cross-linkage of the study database and the regional intranet network allowed access to the electronic medical record to determine deaths and patients lost to follow-up. None of the deaths were related to CRC. NOTE. In the intention-to-treat analysis, the detection rate was calculated as the number of subjects with true-positive results divided by the number of subjects who were eligible to undergo testing. In the per-protocol analysis, the detection rate was calculated as the number of positive results divided by the number of subjects who actually underwent screening according to the assigned group. Subjects were classified according to the most advanced lesion. a ORs were adjusted according to age, sex, age (younger than 60 years or 60 years or older) of the index case at diagnosis of CRC, having siblings with CRC or more than one first-degree relative with CRC.
b Advanced adenoma was defined as an adenoma measuring !10 mm in diameter, with villous architecture, high-grade dysplasia, or intramucosal carcinoma. c Advanced neoplasia was defined as advanced adenoma or cancer.
FIT group and in 38 of 42 (90.5%) in the colonoscopy group: 5 and 2 advanced adenomas were detected, respectively. At study completion, 703 (97.0%) subjects in the FIT group and 756 (94.7%) in the colonoscopy group were successfully contacted after a median follow-up of 55 months (range, 3-94 months) from inclusion in either study group. No cases of interval cancer were recorded in either group. Twelve deaths in the FIT group and 6 in the colonoscopy group were recorded, all unrelated to CRC. Overall, 21 (2.9%) subjects in the FIT group and 42 (5.2%) in the colonoscopy group were lost to follow-up.
Discussion
In this prospective randomized trial involving firstdegree relatives of sporadic CRC index cases, repeated FIT screening detected all CRC and 61% of advanced adenomas, proving equivalent to one-time colonoscopy screening in terms of diagnostic yield and tumor staging. However, colonoscopy was superior to the FIT strategy for the detection of any neoplasm. The study also revealed that the number of subjects requiring colonoscopy to detect one advanced neoplasm was 4 times less in first-degree relatives screened by FIT than in those screened by colonoscopy. This finding indicates that FIT screening may save a large amount of unnecessary colonoscopies in this population.
Our study has a number of strengths. First, it is the first randomized trial to compare colonoscopy with FIT screening in familial CRC. Second, considering that the noninvasive nature of the FIT screening strategy can compensate for its lower capacity for detecting advanced neoplasia with respect to colonoscopy by increasing the screening uptake, we designed an equivalence analysis including consecutive screening-naïve first-degree relatives. Third, the trial was carried out in accordance with the strict requirements of an equivalence study. 31, 32 Equivalence was an a priori research aim and assessed on the basis of intention-to-screen and per-protocol analyses. First-degree relatives were randomly assigned to either screening strategy; an equivalence boundary (±3%) was established for the detection of advanced neoplasia and sample size was calculated for equivalence. Finally, follow-up was completed in >95% of individuals in both arms of the study.
The main finding of our study was that cumulative FIT screening yielded an equivalent advanced neoplasia detection rate to one-time colonoscopy. Equivalence between the 2 strategies was supported by the fact that the 95% CI of the advanced neoplasia detection rate difference was within the predefined equivalence boundary (±3%) at different participation rates. The error margin of ±3% was empirically established, considering that it was clinically acceptable for a 3-year rescreening period with FIT. In fact, the results obtained in the current study were better than expected. For an estimated advanced neoplasia global prevalence of 7.7%, with detection rates of 56.5% for FIT and 96.5% for colonoscopy, we expected to find an advanced neoplasia detection rate of 4.4% and 7.4% for FIT and colonoscopy groups, respectively. However, in the intentionto-screen analysis, we found an advanced neoplasia detection rate of 4.2% and 5.6% for the FIT and colonoscopy strategies, respectively, which was less than expected. The most plausible explanation for this finding is that the global prevalence of advanced neoplasia in this population was lower than that expected a priori, which could be directly related to the fact that >50% of participants were younger than 50 years of age. Equivalence was achieved despite suboptimal compliance with the FIT strategy in our study, as only 72.6% of subjects underwent at least 2 tests. This finding was in concordance with a longitudinal study performed in an average-risk population showing similar compliance with FIT screening. 33 The yield of FIT to detect advanced neoplasia in familial CRC varied according to the cutoff value established for fecal Hb detection. A recent cross-sectional study testing a qualitative FIT at a high cutoff level (50 mg Hb/g of feces, equivalent to 250 ng Hb/mL buffer) showed low sensitivity for CRC (25%) and for advanced adenoma (35%) in this population. 34 However, the elevated advanced neoplasia miss rate using this cutoff value makes it unacceptable in screening programs. 35 By contrast, when the cutoff level is decreased to 10 mg Hb/g feces (equivalent to 50 ng Hb/mL buffer), as used in the current study, sensitivity for CRC reached 100%, and for advanced adenoma it ranged from 37% to 85%. 20, 21, 35 The false-negative rate for advanced adenoma detection in these studies varied from 16.6% to 37.5%. In our longitudinal study, a colonoscopy performed in 86.3% of patients who tested negative for FIT confirmed that repeated FIT screening detected all CRC and 25 out of 41 advanced adenomas, that is, a false-negative rate of 39% for advanced adenoma. Advocates of colonoscopy might argue that it is unacceptable to miss 39% of advanced adenomas, and others might consider that a 61% sensitivity with only 3 years of screening is a very good result. Considering that large polyps (>1 cm in diameter) become CRC at a rate of roughly 1% per year, 36 a screening program such as annual FIT, allows the detection of most advanced adenomas on subsequent screens before they become malignant. All together, these findings indicate that repeated FIT screening at a cutoff value of 10 mg Hb/g feces has an acceptable advanced neoplasia yield in this moderate-risk population.
In agreement with previous studies carried out in the average-risk 37 and familial CRC risk populations, 19, 20, 38 we found that FIT screening was associated with a significantly lower detection rate of nonadvanced adenomas than colonoscopy. This finding could be considered an advantage of FIT, as most of these lesions are probably low risk and less likely to progress to CRC than advanced adenomas. 39 If, as in average-risk individuals, the presence of <3 nonadvanced adenomas implies a risk similar to that of individuals without adenomas, 40 this finding could help save unnecessary colonoscopy in the familial-risk population. However, the real clinical significance of nonadvanced lesions in this moderate-risk group remains to be clarified.
The usefulness of FIT screening as an alternative to colonoscopy in the familial risk population will finally depend on the capacity of FIT to improve screening uptake. This question cannot be answered by the current study, as the uptake of first-degree relatives assigned to the FIT group was influenced by the fact that most were referred to our high-risk CRC clinic to undergo colonoscopy screening, and also because the study design included colonoscopy after 3 years of FIT screening, if so desired.
We are also aware of the study limitations. First, as stated, we could not evaluate the efficacy of annual FIT screening for a period longer than 3 years due to ethical concerns, a fact that could have had improved FIT performance. Second, a potential bias for increased detection of advanced neoplasia in the FIT group was possible, as participants knew that they could opt out of their assigned screening strategy before signing informed consent. However, this limitation was minimized by the per-protocol analysis, which corroborated there was no significant difference in the detection rate of advanced neoplasia between the 2 arms of the study. Third, we cannot provide accurate information as to whether repeated FIT is able to detect sessile serrated polyps or traditional serrated polyps, because at the time the study was designed (2006), these polyps were classified as hyperplastic and considered to have no malignant potential. In fact, clinical guidelines did not recommend colonoscopy surveillance for individuals with these polyps until recently.
9 Fourth, the current study was not powered to analyze the different risk groups separately. However, the higher-risk subgroup of first-degree relatives having at least 2 family members with CRC constituted a small minority (7.6%) of the whole study sample. To minimize the effect of this potential flaw, the analysis was adjusted for confounding variables, including index-case age and having siblings or more than one family member with CRC. In addition, both arms of the study were homogeneous regarding demographic data and family history.
Finally, the potential advantage of FIT screening to spare endoscopic resources in this moderate-risk population also warrants comment. First, the number of first-degree relatives that needed to undergo colonoscopy to detect one advanced neoplasia was 4 in the FIT group as compared with 18 in the colonoscopy group. Second, up to 71% of colonoscopies in the colonoscopy arm had a normal or nonsignificant result. Overall, repeated screening with FIT needed about 86% fewer colonoscopies to detect 100% CRC and 61% of advanced adenomas, which is consistent with the results of previous studies. 19, 41 Therefore, a potential benefit of FIT over primary colonoscopy in familial CRC screening is that it may save a substantial number of unnecessary colonoscopies, thus preventing harm and lowering costs. Given its equivalence in terms of advanced neoplasia detection, FIT screening should be considered when colonoscopy capacity is limited.
In conclusion, the results of this randomized trial demonstrate that in asymptomatic first-degree relatives of patients with CRC, screening with FIT is equivalent to onetime colonoscopy for the detection of advanced neoplasia. In addition, it also provides evidence for the benefit of repeated FIT screening in terms of colonoscopy resources. This strategy should be taken into account when colonoscopy capacity is limited and particularly in populations where FIT is better accepted than colonoscopy as a CRC screening strategy. Additional studies are needed to determine acceptance of this strategy and its efficacy in reducing the incidence and mortality associated with familial CRC.
